Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 13/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RARA | P10276 | 1/20 | 0.33 |
| ▸ | RARB | P10826 | 1/20 | 0.33 |
| ▸ | RARG | P13631 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10275809 | 0.84 | NR3C2 (0.39) | NR3C2ARALDH1A1RARARARB | |
| SCHEMBL10275578 | 0.69 | SIRT5 (0.40) | NR3C2ARRARARARBRARG | |
| SCHEMBL10276267 | 0.67 | KDM1A (0.34) | AR | |
| SCHEMBL10276242 | 0.67 | NR3C2 (0.38) | NR3C2ARRARARARBRARG | |
| SCHEMBL10276245 | 0.67 | NR3C2 (0.38) | NR3C2ARRARARARBRARG | |
| SCHEMBL10276404 | 0.63 | KDM1A (0.35) | AR | |
| SCHEMBL307426 | 0.62 | MAP4K4 (0.60) | ARMAP4K4 | |
| Hydrochloric Acid SCHEMBL15939679 | 0.61 | MAP4K4 (0.59) | ARMAP4K4 | |
| SCHEMBL216706 | 0.61 | CA2 (0.64) | ARALDH1A1RARBRARGMAP4K4 | |
| SCHEMBL1231896 | 0.60 | SLC22A12 (0.56) | ARRARARARBRARGMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | NR3C2 1731/4885AR 3221/4885ALDH1A1 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.